Lawyers Warn Time Running Out to File Yaz Lawsuits for Blood Clots

Wednesday, August 27, 2014

Last month, German drug manufacturer Bayer released their latest financial reports showing sales of the once-leading birth control pill Yaz has slowed by more than 10% in the past year.

Hidden deep in those records was additional information showing the company has spent nearly $2 billion on settlements for those who have been hospitalized for blood clots issues like stroke, deep vein thrombosis or pulmonary embolism.

Now, lawyers are warning that the settlements that have been ongoing for years could be close to conclusion. They are urging anyone who may qualify to file a claim as soon as possible.

Bayer originally faced more than 11,000 lawsuits from women around the United States who had suffered severe side effects like blood clots. Some of the claims even involved patient death.

The company chose to settle many of these cases rather than face the public attention of trials. They have now settled more than 10,000 cases for blood clots or gallbladder injury, with the average for Yaz blood clot settlements at more than $200,000 per victim.

This month, a special federal panel tasked with handling the Yaz claims in a central court reported that 8,433 were still pending as of August 15th.

However, lawyers caution that those affected may soon face statute of limitation restrictions if they don’t take action to preserve their legal rights. Also, they can only file a Yaz lawsuit if their injury occurred prior to June of 2012.

birth control

Other drugs and devices in the news:

Friday, August 9, 2019
Surgical Stapler
Did Surgical Staple Companies Hide Thousands of Injuries?

This past spring, the FDA issued a warning affecting the millions of patients each year that undergo routine gastrointestinal, gynecologic...

Friday, August 2, 2019
Invokana Gangrene Amputation
Federal Panel Adds Fournier's Gangrene to Crowded Invokana MDL Court

In the latest Invokana lawsuit update, DrugNews has learned that a federal judicial panel has transferred new cases alleging...

Get in touch with us.

Call, email or live chat with us today to see how we can help.

Need a quick answer? Call us!
Reach out to us by email.
live chat with DrugNews
We are here to help now